Skip to main content
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · TLX ISIN · AU000000TLX2 ASX Manufacturing
Open in API
Filings indexed 989 across all filing types
Latest filing 2024-11-18 Capital/Financing Update
Country US United States of America
Listing ASX TLX

About Telix Pharmaceuticals Ltd

https://telixpharma.com/

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, an approach known as 'theranostics'. The company utilizes targeted radiation to both image and treat various forms of cancer. Its extensive clinical pipeline and portfolio address key areas in oncology, including urologic (prostate and kidney), neurologic (glioma), and musculoskeletal cancers, as well as applications in bone marrow conditioning. Telix has secured global regulatory approvals for its prostate cancer imaging agent and supports its products with a robust global supply, manufacturing, and distribution network. The company is actively engaged in numerous clinical trials worldwide to expand its theranostic platform.

Recent filings

Filing Released Lang Actions
Telix Adds FAP-Targeting Theranostic Candidates to Pipeline 3 pages 151.0KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement from Telix Pharmaceuticals Limited dated 19 November 2024. It details the company's expansion of its theranostic pipeline through asset purchase and licensing agreements related to Fibroblast Activation Protein (FAP) targeting candidates. The content focuses on the business development and strategic pipeline update, including deal terms and conditions, milestone payments, and regulatory approvals required for closing. There are no financial statements, quarterly or annual results, nor is this a transcript or presentation. The document is a corporate announcement about a capital/financing-related transaction (asset purchase and licensing agreements with milestone payments). It is not a full financial report or earnings release but an update on financing and capital structure through acquisition and licensing deals. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (over 10,000 characters) and detailed deal terms confirm it is not a mere announcement of a report (RPA) or a regulatory filing (RNS).
2024-11-18 English
Presentation to Accompany FAP-Targeting Acquisition 14 pages 1.5MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation discussing a strategic transaction to add clinically-validated Fibroblast Activation Protein (FAP) assets to the pipeline of Telix Pharmaceuticals. It includes scientific background, clinical evidence, market opportunity, and strategic rationale. The text contains forward-looking statements, detailed scientific and clinical data, and market analysis. It is structured as a presentation with slides and images (omitted here), and it is intended for investors or stakeholders to understand the company's strategic development and pipeline expansion. There is no indication that this is a formal regulatory filing, annual or interim report, earnings release, or legal proceeding. The content aligns with an investor presentation focusing on financials, strategy, and market position rather than a formal report or announcement. Therefore, the most appropriate classification is Investor Presentation (IP).
2024-11-18 English
6-K
Regulatory Filings
2024-11-14 English
Telix ADSs Commence Trading on Nasdaq 2 pages 130.7KB
Capital/Financing Update Classification · 95% confidence The document is an announcement from Telix Pharmaceuticals Limited regarding the commencement of trading of its American Depository Shares (ADSs) on the Nasdaq Global Select Market. It states that no new shares were issued and provides details about the listing and the depositary bank. The document is an ASX announcement and does not contain financial statements, detailed financial data, or management discussion of results. It is a regulatory announcement about a capital market event (listing of ADSs) but not a financing update involving new capital issuance. It is not a full financial report, earnings release, or investor presentation. The document is best classified as a Capital/Financing Update (CAP) because it informs about a significant capital market event related to the company's securities and listing status.
2024-11-13 English
Securities Dealing Policy - Updated 11 pages 304.2KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Telix Pharmaceuticals Limited dated 14 November 2024. It announces an update to the company's Securities Dealing Policy, effective 13 November 2024, and includes the full text of the updated policy. The content focuses on insider trading prohibitions, definitions, and policy application rather than financial results, management changes, or other report types. The document is lengthy (15,000 characters) and contains the full policy text, not just a brief notice or link to a report. It is not a financial report, earnings release, or management discussion. It is also not a regulatory filing in the sense of officer certifications or miscellaneous filings, but rather a formal policy update announcement. The closest fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories. Therefore, the document is best classified as Regulatory Filings (RNS).
2024-11-13 English
Regulatory Filings 2024
Regulatory Filings
2024-11-13 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.